For the Inventor, By the Inventor

Enter inventor name

Biberach an der Riss, Germany

Michael Mark

USPTO Granted Patents = 49 (Patent Applications = 73)

CIPO Patents = 13

EPO Patents = 23 (Patent Applications = 50)

Average Co-Inventor Count = 4.6

ph-index = 22

Forward Citations = 1,410(Granted Patents)

Location History:

Biberach, DE (1991 - 2014)
Biberach an der Riss, DE (2014 - 2024)

Company Filing History:

28 out of 1,536

Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharma Gmbh & Co Kg

Boehringer Ingelheim Pharma Kg

4. 4 out of 133

Dr. Karl Thomae Gmbh

Karl Thomae Gmbh

Years Active: 1991-2025

Loading Chart...

Loading Chart...

Loading Chart...

Areas of Expertise:

DPP-4 Inhibitors

Diabetes Therapy

Pharmaceutical Composition

Combination Therapy

Xanthine Derivatives

Imidazopyridazinone Derivatives

Vasoprotective Therapy

Cardioprotective Therapy

Nephrotic Syndrome

Genotyped Diabetic Patients

Food Intake Regulation

Cholesterol Biosynthesis Inhibitors

49 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12312352 - Use of a DPP-4 inhibitor in SIRS and/or sepsis (2025-05-27),

2. 12171767 - Uses of DPP IV inhibitors (2024-12-24),

3. 12115179 - Pharmaceutical composition, methods for treating and uses thereof (2024-10-15),

4. 11911388 - Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug (2024-02-27),

5. 11911387 - Vasoprotective and cardioprotective antidiabetic therapy (2024-02-27),

6. 11291668 - Uses of DPP IV inhibitors (2022-04-05),

7. 10406172 - Pharmaceutical composition, methods for treating and uses thereof (2019-09-10),

8. 10195203 - Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome (2019-02-05),

9. 10092571 - Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin (2018-10-09),

10. 10080754 - Uses of DPP IV inhibitors (2018-09-25),

11. 10004747 - Combination therapy (2018-06-26),

12. 9713618 - Method for modifying food intake and regulating food preference with a DPP-4 inhibitor (2017-07-25),

13. 9603851 - Combination therapy (2017-03-28),

14. 9556175 - 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and thier use as pharmaceutical compositions (2017-01-31),

15. 9526730 - Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome (2016-12-27),

Title: Inventor Michael Mark

Introduction: Michael Mark is a renowned inventor based in Biberach an der Riss, Germany, known for his groundbreaking contributions to various fields.

Latest Patents: Michael Mark holds several patents in the areas of renewable energy technologies, medical devices, and advanced materials.

Career Highlights: With a career spanning over two decades, Michael Mark has worked with leading research institutions and companies to develop innovative solutions that have had a significant impact on society.

Collaborations: Throughout his career, Michael Mark has collaborated with top scientists, engineers, and experts in multidisciplinary projects, resulting in the successful commercialization of several inventions.

Conclusion: Michael Mark's dedication to pushing the boundaries of innovation and his passion for creating solutions to complex challenges make him a key figure in the world of inventors.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…